With the loss of exclusivity, several companies, including Sandoz, Apotex, Teva, Taro, Vimy Pharma, Hims & Hers, and Biocon, have filed applications to launch generic versions of semaglutide, but they are pending Health Canadas regulatory approval
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
During your treatment, you may experience weight loss and a decrease in appetite, which can be positive side effects for those looking to manage their diabetes
What do specialized weight management clinics offer
Because semaglutide supports weight loss by mimicking a natural hormone, its structure must be intact to fit into your bodys receptors
